Only a few cases of functional knockout of the Nrf2 gene by CRISPR/Cas9 have been reported—in human lung cancer cells (A549), human embryonic stem cells24,25, and, recently, in the human colorectal cancer cell line DLD126, where isogenic wild-type cells, CRISPR/Cas9 generated Nrf2-KO cells and gain-of-function Nrf2 cells were compared. This evidence concerns the gene NFE2L2 and lung cancer.